• Product NameGefitinib (ZD1839)
• Brief DescriptionInhibitors
• Purification99.92%
• Biological ActivityGefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of Y. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
• Target NameTyrosine Kinases inhibitor
• CAS No. 184475-35-2
• Calculated MW 446.91
• Formulation C22H24ClFN4O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
  Pathways:Proteases/Proteasome
  Receptor:Tyr1173 (NR6W cells); Tyr1173 (NR6wtEGFR cells); Tyr992 (NR6W cells); Tyr992 (NR6wtEGFR cells)
  Boling pt:
  Melting pt:290C
  Solubility:Ethanol: 4 mg/mL (8.95 mM); DMSO: 89 mg/mL (199.14 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Ciardiello F, et al. Clin Y Res. 2000 May;6(5):2053-63.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting